The company's devices, BioZorb Marker and BioZorb LP Marker, are implanted in soft tissue, including breast tissue, where the site needs to be marked for future procedures, such as radiation for breast cancer treatment. The Food and Drug Administration said it has received reports on complications related to the use of the devices in breast tissue including infection, fluid buildup, device moving out of its position and breaking through the skin. It has also received reports of pain, discomfort from feeling the device in the breast along with the need for additional medical treatment for the removal of the device.
The Food and Drug Administration (FDA) is looking into reports of adverse side effects from using diabetes medications such as Ozempic and Mounjaro, with hair loss, suicidal thoughts and airway obstruction being among the reported complications. According to the latest information from the agency, the FDA Adverse Event Reporting System (FAERS) received reports of patients…